- Changes will become effective prior to the open next Monday. ETF: IBB
- Added: Arbutus (NASDAQ:ABUS), Aclaris (NASDAQ:ACRS), Adaptimmune (NASDAQ:ADAP), Achaogen (NASDAQ:AKAO), Akcea (NASDAQ:AKCA), AnaptysBio (NASDAQ:ANAB), Ascendis (NASDAQ:ASND), Athenex (NASDAQ:ATNX), Aurinia (NASDAQ:AUPH), Axovant (NASDAQ:AXON), Bioverativ (NASDAQ:BIVV), Calithera (NASDAQ:CALA), Cara (NASDAQ:CARA), Cascadian (NYSE:CASC), Cellectis (NASDAQ:CLLS), Calyxt (NASDAQ:CLXT), Chimerix (NASDAQ:CMRX), Concert (NASDAQ:CNCE), Corium (NASDAQ:CORI), Corbus (NASDAQ:CRBP), Crispr (NASDAQ:CRSP), Corvus (NASDAQ:CRVS), CytomX (NASDAQ:CTMX), Dova (NASDAQ:DOVA), Endocyte (NASDAQ:ECYT), Galapagos (NASDAQ:GLPG), GlycoMimetics (NASDAQ:GLYC), G1 Thera (Pending:GTHX), ImmunoGen (NASDAQ:IMGN), Jounce (NASDAQ:JNCE), Kala (Pending:KALA), Kura (NASDAQ:KURA), Medpace (NASDAQ:MEDP), MannKind (NASDAQ:MNKD), Marinus (NASDAQ:MRNS), Mersana (NASDAQ:MRSN), MyoKardia (NASDAQ:MYOK), Nabriva (NASDAQ:NBRV), Neos (NASDAQ:NEOS), Puma (NYSE:PBYI), PetIQ (Pending:PETQ), uniQure (NASDAQ:QURE), Ra Pharma (NASDAQ:RARX), Reata (NASDAQ:RETA), Strongbridge (NASDAQ:SBBP), Syndax (NASDAQ:SNDX), Sienna (Pending:SNNA), Savara (NASDAQ:SVRA), Tocagen (Pending:TOCA), Tetraphase (NASDAQ:TTPH), TherapeuticsMD (NYSEMKT:TXMD), Vital (NASDAQ:VTL), Voyager (NASDAQ:VYGR).
- Removed: Aquinox (NASDAQ:AQXP), Aralez (NASDAQ:ARLZ), Compugen (NASDAQ:CGEN), Clearside (NASDAQ:CLSD), Impax Lab (NASDAQ:IPXL), Merrimack (NASDAQ:MACK), Cempra (NASDAQ:MLNT), Medicinova (NASDAQ:MNOV), OncoMed (NASDAQ:OMED), Organovo (NASDAQ:ONVO), Ophthotech (NASDAQ:OPHT), Otonomy (NASDAQ:OTIC), Trevana (NASDAQ:TRVN), Versartis (NASDAQ:VSAR), XBiotech (NASDAQ:XBIT).
- Source: Press Release
- Now read: The Investment Case For Ascendis Pharma
Original article